Old and New Systemic Immune-Inflammation Indexes Are Associated with Overall Survival of Glioblastoma Patients Treated with Radio-Chemotherapy

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2022 Jun 24

PMID 35741816

Authors

Francesco Pasqualetti

Celeste Giampietro

Nicola Montemurro

Noemi Giannini

Giovanni Gadducci

Paola Orlandi

Eleonora Natali

Paolo Chiarugi

Alessandra Gonnelli

Martina Cantarella

Cristian Scatena

Giuseppe Nicolo Fanelli

Antonio Giuseppe Naccarato

Paolo Perrini

Gaetano Liberti

Riccardo Morganti

Maria Franzini

Aldo Paolicchi

Giovanni Pellegrini

Guido Bocci

Fabiola Paiar

Affiliations

Soon will be listed here.

Abstract

. Systemic immunity and inflammation indexes (SI) derived from blood cells have gained increasing attention in clinical oncology as potential biomarkers that are associated with survival. . We tested 12 different SI using blood tests from patients with isocitrate dehydrogenase 1 and 2 wild-type glioblastomas, treated with radio-chemotherapy. The primary endpoint was their overall survival. . A total of 77 patients, comprising 43 males and 34 females, with a median age of 64 years (age range 26-84), who were treated between October 2010 and July 2020, were included in the present analysis (approved by a local ethics committee). In the univariate Cox regression analysis, all the indexes except two showed a statistically significant impact on OS. In the multivariate Cox regression analysis, neutrophil × platelet × leukocyte/(lymphocyte × monocyte) (NPW/LM) and neutrophil × platelet × monocyte/lymphocyte (NPM/L) maintained their statistically significant impact value. . This univariate analysis confirms the potential of systemic inflammation indexes in patients with glioblastoma, while the multivariate analysis verifies the prognostic value of NPW/LM and NPM/L.

Citing Articles

Systemic inflammatory markers and volume of enhancing tissue on post-contrast T1w MRI images in differentiating true tumor progression from pseudoprogression in high-grade glioma.

Satragno C, Schiavetti I, Cella E, Piciche F, Falcitano L, Resaz M Clin Transl Radiat Oncol. 2024; 49:100849.

PMID: 39318678 PMC: 11419878. DOI: 10.1016/j.ctro.2024.100849.

Heterogeneity and individualized treatment of microenvironment in glioblastoma (Review).

Kang W, Mo Z, Li W, Ma H, Zhang Q Oncol Rep. 2023; 50(6).

PMID: 37888767 PMC: 10636722. DOI: 10.3892/or.2023.8654.

Forkhead box transcription factors (FOXOs and FOXM1) in glioma: from molecular mechanisms to therapeutics.

Tabnak P, Hasanzade Bashkandi A, Ebrahimnezhad M, Soleimani M Cancer Cell Int. 2023; 23(1):238.

PMID: 37821870 PMC: 10568859. DOI: 10.1186/s12935-023-03090-7.

Cell-Free miRNAs as Non-Invasive Biomarkers in Brain Tumors.

Beylerli O, Encarnacion Ramirez M, Shumadalova A, Ilyasova T, Zemlyanskiy M, Beilerli A Diagnostics (Basel). 2023; 13(18).

PMID: 37761255 PMC: 10529040. DOI: 10.3390/diagnostics13182888.

Immuno markers in newly diagnosed glioblastoma patients underwent Stupp protocol after neurosurgery: a retrospective series.

Gurrieri L, Mercatali L, Ibrahim T, Fausti V, DallAgata M, Riva N J Neurooncol. 2023; 164(1):55-64.

PMID: 37584750 PMC: 10462527. DOI: 10.1007/s11060-023-04357-9.

References

Uribe-Querol E, Rosales C . Neutrophils in Cancer: Two Sides of the Same Coin. J Immunol Res. 2016; 2015:983698. PMC: 4706937. DOI: 10.1155/2015/983698. View

Khan S, Mittal S, McGee K, Alfaro-Munoz K, Majd N, Balasubramaniyan V . Role of Neutrophils and Myeloid-Derived Suppressor Cells in Glioma Progression and Treatment Resistance. Int J Mol Sci. 2020; 21(6). PMC: 7139844. DOI: 10.3390/ijms21061954. View

Fanelli G, Grassini D, Ortenzi V, Pasqualetti F, Montemurro N, Perrini P . Decipher the Glioblastoma Microenvironment: The First Milestone for New Groundbreaking Therapeutic Strategies. Genes (Basel). 2021; 12(3). PMC: 8003887. DOI: 10.3390/genes12030445. View

Marini A, Dobran M, Aiudi D, Pesaresi A, di Somma L, Iacoangeli M . Pre-operative hematological markers as predictive factors for overall survival and progression free survival in glioblastomas. Clin Neurol Neurosurg. 2020; 197:106162. DOI: 10.1016/j.clineuro.2020.106162. View

Wang D, Kang K, Lin Q, Hai J . Prognostic Significance of Preoperative Systemic Cellular Inflammatory Markers in Gliomas: A Systematic Review and Meta-Analysis. Clin Transl Sci. 2019; 13(1):179-188. PMC: 6951460. DOI: 10.1111/cts.12700. View

Wang Q, Tan X, Deng G, Fu S, Li J, Li Z . Dynamic changes in the systemic immune-inflammation index predict the prognosis of EGFR-mutant lung adenocarcinoma patients receiving brain metastasis radiotherapy. BMC Pulm Med. 2022; 22(1):75. PMC: 8895866. DOI: 10.1186/s12890-022-01866-7. View

Han S, Liu Y, Li Q, Li Z, Hou H, Wu A . Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC Cancer. 2015; 15:617. PMC: 4559944. DOI: 10.1186/s12885-015-1629-7. View

Sippel T, White J, Nag K, Tsvankin V, Klaassen M, Kleinschmidt-DeMasters B . Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res. 2011; 17(22):6992-7002. DOI: 10.1158/1078-0432.CCR-11-1107. View

Hiam-Galvez K, Allen B, Spitzer M . Systemic immunity in cancer. Nat Rev Cancer. 2021; 21(6):345-359. PMC: 8034277. DOI: 10.1038/s41568-021-00347-z. View

10.

Yan Q, Ertao Z, Zhimei Z, Weigang D, Jianjun P, Jianhui C . Systemic immune-inflammation index (SII): A More Promising Inflammation-Based Prognostic Marker for Patients with synchronic colorectal peritoneal carcinomatosis. J Cancer. 2020; 11(18):5264-5272. PMC: 7391211. DOI: 10.7150/jca.46446. View

11.

Liang J, Piao Y, Holmes L, Fuller G, Henry V, Tiao N . Neutrophils promote the malignant glioma phenotype through S100A4. Clin Cancer Res. 2013; 20(1):187-98. PMC: 4422653. DOI: 10.1158/1078-0432.CCR-13-1279. View

12.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

13.

Wen P, Macdonald D, Reardon D, Cloughesy T, Sorensen A, Galanis E . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010; 28(11):1963-72. DOI: 10.1200/JCO.2009.26.3541. View

14.

Zhang Y, Chen Z, Jin F, Guo D, Chen Q, Liu Z . The Value of the Systemic Immune-Inflammation Index in Predicting Survival Outcomes in Patients with Brain Metastases of Non-Small-Cell Lung Cancer Treated with Stereotactic Radiotherapy. Mediators Inflamm. 2021; 2021:2910892. PMC: 8570891. DOI: 10.1155/2021/2910892. View

15.

Yu D, Liu B, Zhang L, Du K . Platelet count predicts prognosis in operable non-small cell lung cancer. Exp Ther Med. 2013; 5(5):1351-1354. PMC: 3671769. DOI: 10.3892/etm.2013.1003. View

16.

Perrini P, Gambacciani C, Weiss A, Pasqualetti F, Delishaj D, Paiar F . Survival outcomes following repeat surgery for recurrent glioblastoma: a single-center retrospective analysis. J Neurooncol. 2016; 131(3):585-591. DOI: 10.1007/s11060-016-2330-7. View

17.

Karpatkin S, Pearlstein E . Role of platelets in tumor cell metastases. Ann Intern Med. 1981; 95(5):636-41. DOI: 10.7326/0003-4819-95-5-636. View

18.

Wesseling P, Capper D . WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2017; 44(2):139-150. DOI: 10.1111/nan.12432. View

19.

Powell D, Huttenlocher A . Neutrophils in the Tumor Microenvironment. Trends Immunol. 2015; 37(1):41-52. PMC: 4707100. DOI: 10.1016/j.it.2015.11.008. View

20.

Topkan E, Besen A, Ozdemir Y, Kucuk A, Mertsoylu H, Pehlivan B . Prognostic Value of Pretreatment Systemic Immune-Inflammation Index in Glioblastoma Multiforme Patients Undergoing Postneurosurgical Radiotherapy Plus Concurrent and Adjuvant Temozolomide. Mediators Inflamm. 2020; 2020:4392189. PMC: 7262659. DOI: 10.1155/2020/4392189. View